

Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. *Blood Adv*. 2021;5(6):1695-1705.

Page 1695: The data sharing statement in the footnotes, "Data requests may be submitted to Celgene, a Bristol-Myers Squibb company, at <https://vivli.org/ourmember/celgene/> and must include a description of the research proposal," should read "Bristol Myers Squibb policy on data sharing may be found at <https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html>."

Page 1699, Table 2: Under "CRS only (n = 47)*" and "NE only (n = 14)*," the column heading "Grade ≥ 3 " should read "Grade 3."

Page 1700, Table 3: In the left column, under "CRS only" and "NE only," " ≥ 3 " should read "3."

Page 1701, Table 4: Under "CRS only (n = 47)*" and "NE only (n = 14)*," the column heading "Grade ≥ 3 " should read "Grade 3."

Page 1702, Table 5: Under "CRS only (n = 47)*" and "NE only (n = 14)*," the column heading "Grade ≥ 3 " should read "Grade 3." In the second row of the left column, "otal" should read "total."

Page 1703, Figure 2: The label for the fourth bar from the right, "CRS & NE Grade ≥ 3 (n = 5)," should read, "CRS or NE Grade ≥ 3 (n = 5)."

<https://doi.org/10.1182/bloodadvances.2021005392>

© 2022 by The American Society of Hematology